🔬 Peptide Sciences has shut down. Looking for an alternative? You found it.

CALIBERPEPTIDES

Cagrisema

⚡

Cagrisema

Premium Dual-Pathway

5mg (2.5+2.5) × 10 vials — Weight Loss

10 vials — 12 months supply

Seen as Novo Nordisk's answer to tirzepatide. Growing interest following REDEFINE trial publications.

$445

= $1.22/day

What it does

Cagrisema combines Cagrilintide (a long-acting amylin analogue) with Semaglutide (GLP-1 agonist). Amylin works in the brainstem to produce feelings of fullness, while GLP-1 acts on the hypothalamus to reduce appetite. The dual pathway produces stronger appetite suppression than either compound alone.

This is Novo Nordisk's premium combination approach, targeting two distinct satiety pathways for maximum effect.

Dosage & Protocol

Subcutaneous injection, once weekly. Gradual titration over 16-20 weeks. Target: 2.4mg cagrilintide + 2.4mg semaglutide. 10 vials provides approximately 12 months at maintenance.

Duration

12 months

Format

10-vial protocol box

Purity

99%+ (CoA verified)

Delivery

7-14 days worldwide

What to expect

1

Week 1-4: Moderate appetite suppression during titration. Slightly stronger initial effect than semaglutide alone due to dual pathway.

2

Week 4-12: Progressive appetite reduction. Weight loss accelerates as doses increase.

3

Week 12-28: Strong consistent weight loss. Dual mechanism creates more profound satiety than semaglutide alone.

4

Week 28-68: REDEFINE 1 showed 22.7% body weight loss at 68 weeks. REDEFINE 2 showed 15.7% in T2D patients.

Who it's for

Researchers studying combination protocols for maximum metabolic impact

Those who have reached a plateau with single-pathway compounds

Premium protocol researchers looking for the strongest available combination

Anyone studying amylin pathway modulation alongside GLP-1

📖

Read the full Cagrisema profile in the Peptide Bible

Dosing protocols, stacking guides, safety data, and research references.

The research

📄

REDEFINE 1 (NEJM): 22.7% weight loss at 68 weeks with coadministered cagrilintide and semaglutide(NEJMoa2502081)

📄

REDEFINE 2: 15.7% weight loss in adults with T2D(40544432)

Safety notes

⚠️Similar GI profile to semaglutide — nausea, vomiting, diarrhea. May be slightly more frequent due to dual mechanism.

⚠️Phase 3 complete, awaiting FDA submission. Not yet approved.

⚠️Do NOT combine with tirzepatide or retatrutide — overlapping mechanisms, excessive GI stress.

Pairs well with

L-Carnitine

Enhanced fat metabolism support

BPC-157

GI support

Complete Your Protocol

Full Year Protocol

Dual-Action Protocol

Bacteriostatic Water

Essential for Reconstitution

Frequently Asked Questions

Start My Premium Dual-Pathway

5mg × 10 vials — 12 months supply — $445 — $1.22/day

Includes Peptide Bible, CoA certificate, and Telegram support